Jason Wall

418 total citations
6 papers, 345 citations indexed

About

Jason Wall is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Biotechnology. According to data from OpenAlex, Jason Wall has authored 6 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 2 papers in Pathology and Forensic Medicine and 2 papers in Biotechnology. Recurrent topics in Jason Wall's work include Cell death mechanisms and regulation (3 papers), Cancer Research and Treatments (2 papers) and Cardiac Ischemia and Reperfusion (2 papers). Jason Wall is often cited by papers focused on Cell death mechanisms and regulation (3 papers), Cancer Research and Treatments (2 papers) and Cardiac Ischemia and Reperfusion (2 papers). Jason Wall collaborates with scholars based in United States and United Kingdom. Jason Wall's co-authors include Christopher C. Glembotski, Takahiro Katō, Mark A. Sussman, John A. Muraski, Yasuyuki Tsujita, Mary C. Beckerle, Erik Schaefer, Yan Chen, Joshua J. Martindale and Prafulla Aryal and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Cancer Research.

In The Last Decade

Jason Wall

6 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jason Wall United States 4 238 90 65 47 44 6 345
Yulia Epshtein United States 13 282 1.2× 88 1.0× 35 0.5× 21 0.4× 48 1.1× 24 432
Hasnae Elouardighi United States 8 278 1.2× 115 1.3× 23 0.4× 30 0.6× 41 0.9× 8 440
Ewa Zembala‐Nożyńska Poland 11 135 0.6× 47 0.5× 65 1.0× 33 0.7× 27 0.6× 45 345
Tamlyn Thomas United States 10 255 1.1× 82 0.9× 39 0.6× 13 0.3× 77 1.8× 17 370
Sindy Rabe Germany 12 197 0.8× 81 0.9× 55 0.8× 17 0.4× 24 0.5× 20 324
Guilin Chen China 14 171 0.7× 58 0.6× 53 0.8× 20 0.4× 43 1.0× 36 434
Matthew R. Richardson United States 11 223 0.9× 52 0.6× 34 0.5× 28 0.6× 29 0.7× 13 446
Angela M. Farrelly Ireland 10 256 1.1× 59 0.7× 125 1.9× 24 0.5× 31 0.7× 19 417
Maha M. Lakkis United States 9 376 1.6× 54 0.6× 34 0.5× 23 0.5× 28 0.6× 14 514
Can‐E Tang China 14 386 1.6× 63 0.7× 122 1.9× 48 1.0× 38 0.9× 36 571

Countries citing papers authored by Jason Wall

Since Specialization
Citations

This map shows the geographic impact of Jason Wall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Wall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Wall more than expected).

Fields of papers citing papers by Jason Wall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Wall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Wall. The network helps show where Jason Wall may publish in the future.

Co-authorship network of co-authors of Jason Wall

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Wall. A scholar is included among the top collaborators of Jason Wall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Wall. Jason Wall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Sandall, Sharsti, Marsha L. Mason, Lori Westendorf, et al.. (2019). Abstract 2688: SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors. Cancer Research. 79(13_Supplement). 2688–2688. 2 indexed citations
2.
Kaplan‐Lefko, Paula, Jonathan D. Graves, Stephen J. Zoog, et al.. (2010). Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biology & Therapy. 9(8). 618–631. 100 indexed citations
3.
Wall, Jason, et al.. (2008). AMG 655, a monoclonal antibody agonist directed against Death Receptor 5, induces apoptosis in human colon carcinoma cell lines and its therapeutic potential is enhanced in combination with chemotherapeutic agents. Cancer Research. 68. 1326–1326. 3 indexed citations
4.
Wall, Jason, Jing Wei, Peter J. Belmont, et al.. (2006). Alterations in oxidative phosphorylation complex proteins in the hearts of transgenic mice that overexpress the p38 MAP kinase activator, MAP kinase kinase 6. American Journal of Physiology-Heart and Circulatory Physiology. 291(5). H2462–H2472. 29 indexed citations
5.
Katō, Takahiro, John A. Muraski, Yan Chen, et al.. (2005). Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. Journal of Clinical Investigation. 115(10). 2716–2730. 137 indexed citations
6.
Martindale, Joshua J., Jason Wall, Prafulla Aryal, et al.. (2004). Overexpression of Mitogen-activated Protein Kinase Kinase 6 in the Heart Improves Functional Recovery from Ischemia in Vitro and Protects against Myocardial Infarction in Vivo. Journal of Biological Chemistry. 280(1). 669–676. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026